|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.15/0.97
|
企业价值
1.36B
|
资产负债 |
每股账面净值
2.71
|
现金流量 |
现金流量率
0.02
|
损益表 |
收益
318.00K
|
每股收益
1.11
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/24 12:28 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States. |